Related Experiment Video
Updated: Jan 24, 2026
05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.3K
MIDDLE TERM IMPACT OF SLEEVE GASTRECTOMY ON MAJOR CARDIOVASCULAR RISK FACTORS IN A GROUP OF ROMANIAN OBESE PATIENTS
D Timofte1, I Hristov2, F Zugun-Eloae3
1"Gr. T. Popa" University of Medicine and Pharmacy, Dept. of Surgery, Iasi, Romania.
Acta Endocrinologica (Bucharest, Romania : 2005)
|June 1, 2019
Summary
Laparoscopic sleeve gastrectomy significantly improved metabolic parameters in obese patients, reducing triglycerides, cholesterol, and glucose levels. This bariatric surgery effectively lowers cardiovascular risk factors alongside substantial weight loss.
Area of Science:
- Metabolic Surgery
- Obesity Management
- Cardiovascular Risk Reduction
Background:
- Bariatric surgery aims to reduce body mass index (BMI) and treat obesity comorbidities.
- Laparoscopic sleeve gastrectomy (LSG) is a common bariatric procedure.
- Metabolic syndrome is a prevalent comorbidity in obese patients.
Purpose of the Study:
- To evaluate the impact of LSG on metabolic parameters.
- To assess changes in glucose and lipid profiles post-LSG.
- To determine the effect of LSG on metabolic syndrome criteria.
Main Methods:
- 85 obese patients underwent LSG.
- Serum glucose and lipid fractions were measured at baseline, 6, and 12 months post-surgery.
- Metabolic syndrome criteria were assessed before and after LSG.
Main Results:
- Significant reductions in triglycerides (30%), total cholesterol (12%), and glucose (12%) were observed at 12 months.
- HDL-cholesterol increased by 26% post-LSG.
- Mean excess weight loss (%EWL) was 72% after 12 months.
Conclusions:
- LSG positively impacts lipid fractions and fasting glucose levels.
- Bariatric surgery significantly reduces metabolic syndrome prevalence.
- These improvements contribute to lower cardiovascular risk and enhanced quality of life.
Related Concept Videos
01:26Factors Affecting the Risk of Infection
13.3K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.3K
01:21Drug Dosing: Obese Patients
238
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
238
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
260
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
260
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
175
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
175
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
312
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
312
01:24Obesity
1.2K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.2K